Johnson & Johnson's Q3 2025 earnings exceeded expectations, with $2.80 per share. Sales reached $24.0 billion, up 6.8%, driven by strong performance in the Innovative Medicines segment.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit
